Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…
DEA Update on Diphenidine Scheduling in Controlled Substances Act
The DEA scheduling diphenidine update reflects its placement in Schedule I due to high abuse potential and no accepted medical use. This regulatory action highlights challenges in controlling novel synthetic dissociatives. Clinicians should stay informed…
FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…
Texas Hemp Ban Enforceable During Legal Challenge Court Rules
A Texas court ruled the state's Total THC hemp regulations remain enforceable during ongoing legal challenges, creating immediate uncertainty for patient access to cannabinoid products. The Texas hemp ban enforceable decision means products compliant…
Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 08, 2026
This Policy Watch covers DEA synthetic cannabinoids schedule I placement updates for June 08, 2026. These regulatory actions affect clinical and research practices involving controlled substances. Clinicians should stay informed about these changes to…
Policy Watch: Key Synthetic Cannabinoids Schedule I Updates — June 02, 2026
This policy watch highlights synthetic cannabinoids Schedule I updates 2026 with significant clinical and regulatory implications. The DEA's recent actions classify several synthetic cannabinoids as Schedule I substances, affecting clinicians and…
Frankel Bill Passes to Allow Medical Cannabis Access for Terminally Ill in Hospitals
The medical cannabis access legislation removes barriers for terminally ill patients in hospitals. This law allows clinicians to recommend cannabis for symptom relief such as pain and nausea. It supports patient autonomy and improves end-of-life care…
North Carolina Could Legalize Medical Marijuana Now That It’s Been Federally …
North Carolina's consideration of medical marijuana legalization following federal rescheduling could expand access to cannabis medicine for thousands of patients. Understanding physician certification requirements and qualifying conditions will be…
Tennessee lawmakers split as DOJ shift reignites push for medical marijuana rules
Tennessee's medical cannabis program provides limited patient access through strict regulatory requirements and qualifying conditions. Understanding the state's framework helps patients navigate the complex process of obtaining medical cannabis…